Corporate Governance prize awarded by AGEFI: Onxeo receives “Silver Governance” for the second consecutive year
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, has been awarded for the second consecutive year the “Silver Governance” in the small and midcap companies category at the Twelfth Annual Corporate Governance Awards held by the French financial magazine AGEFI on September 16, 2015.
The Corporate Governance Prizes reward listed companies with the best corporate governance practices, in particular as regards the composition of the companies’ Board of Directors, the transparency of communication, the functioning of corporate bodies, social responsibility, and risk management. The awards are based on the results of a survey of finance industry professionals. The methodology is validated by a steering committee which identifies the companies’ good practices based on data provided in the annual reports and reference documents.
“We are very happy to, once again, be awarded with this prize which reflects the excellence of our governance and our efforts to implement the best corporate processes. These are key in strengthening our shareholders’ and the market’s confidence in Onxeo. Therefore, we will continue to ensure that we are up to the highest standards in these fields”, commented Patrick Langlois, Chairman of the Board of Directors of Onxeo.